Refsum Disease: Peroxisomal Disorder and Accumulation of Phytanic Acid
Refsum disease is an extremely rare autosomal recessive genetic disorder belonging to the
group of peroxisomal biogenesis disorders. It is characterized by abnormal accumulation of
certain fatty substances called phytanic acid within the body's cells and tissues due to
impaired peroxisomal function. This builds up primarily in the nerves, blood vessels, and
retina resulting in a characteristic pattern of multi-system neurologic, cardiac and ocular
involvement. If left untreated, Refsum disease can lead to significant morbidity and even
mortality. However, early suspicion aided by diagnostic testing and specialized therapies
targeting phytanic acid reduction offers hope for improved long term prognosis. This paper
aims to provide a comprehensive overview of Refsum disease covering etiology, clinical
manifestations, diagnosis, management approaches and prognosis.
Genetics and Pathogenesis
Refsum disease arises due to mutations affecting genes encoding peroxisomal membrane or
matrix proteins critical for normal peroxisomal function and assembly. Specifically,
mutations in the PEX1, PEX2, PEX5, PEX6, PEX10, PEX12, PEX13, PEX26 and AGPS
genes which map to chromosomes 1p32, 11q12 and 2p13 have been implicated in Refsum
disease. Peroxisomes are subcellular organelles responsible for various metabolic reactions
including breakdown (catabolism) of very long chain fatty acids, bile acid intermediates and
polyunsaturated fatty acids like phytanic acid derived from ruminant animal fats and dairy
products.
In Refsum disease, dysfunction of the peroxisomal import receptor protein PEX5 due to
mutations prevents transport of catalase and other matrix enzymes into the peroxisome lumen
necessary for phytanic acid α-oxidation. This results in impaired phytanic acid catabolism
and its intracellular accumulation especially within the nervous system, blood vessels and
retina over decades. Phytanic acid is a branched chain saturated fatty acid which incorporates
within membrane phospholipids to cause structural and functional abnormalities. It also
exerts toxic effects by activating oxidative and endoplasmic reticulum stress pathways
inducing inflammatory cytokines and cell death if levels rise sufficiently. Accumulation of
phytanic acid and its lipid-derived metabolites are directly responsible for the multi-systemic
clinical manifestations seen in Refsum disease patients over time.
Clinical Features
The hallmark clinical triad in Refsum disease includes a progressive sensory motor peripheral
neuropathy, retinal degeneration causing night blindness and visual impairment and cardiac
abnormalities. Other associated features include anosmia, hearing loss, cerebellar ataxia,
skeletal abnormalities and coagulopathy.
Neuropathy: Diffuse sensory motor peripheral neuropathy commonly heralds illness onset in
the teenage years with numbness and paresthesias beginning distally in the lower extremities
and later involving hands. Progression results in severe sensory loss, variable degrees of
weakness, muscle wasting and impaired proprioception. Symptoms are often amplified by
cold exposure.
Retinopathy: Bilateral pigmentary retinopathy manifests as an early night blindness followed
by tunnel vision and progressive loss of peripheral vision. Fundus examination demonstrates
bone spicule pigment clumping in the retina and attenuation of retinal arterioles.
Cardiomyopathy: Dilated cardiomyopathy with impaired systolic function appears in adult
illness stages prompting congestive heart failure, arrhythmias and thromboembolism risk.
Cerebellar ataxia: Limb and gait ataxia arise secondarily from neuropathy and cerebellar
involvement evidenced clinically or on neuroimaging as cerebellar atrophy.
Anosmia: Loss of sense of smell affects up to 90% due to olfactory bulb degeneration.
Hearing loss: Sensorineural deafness develops later due to cochlear involvement.
Skeletal abnormalities: Epiphyseal dysplasia of long bones and vertebrae can occur with limb
deformities.
Coagulopathy: Platelet dysfunction, acquired von Willebrand disease and bleeding tendency
get manifested in advanced stages.
Constitutional symptoms: Non-specific complaints like fatigue, anorexia and weight loss
accompany severe multi-organ involvement.
Diagnosis
The presence of a characteristic clinical triad coupled with manifestations of multi-system
involvement should raise suspicion for Refsum disease even in the absence of family history
due to its rarity and genetic heterogeneity. Diagnosis relies on demonstrating elevated
phytanic acid levels in plasma or cultured skin fibroblasts along with exclusion of other
peroxisomal or lipid storage disorders.
Plasma phytanic acid: Elevated >2-3mg/dL in healthy individuals (<1mg/dL). Levels
progressively rise with advancing age and correlate with disease severity. A normal level
does not necessarily exclude the diagnosis though.
Skin fibroblast phytanic acid: Incubation with [3H]phytanic acid to show impaired β-
oxidation and accumulation within cells compared to normal fibroblasts serves as a highly
sensitive and specific diagnostic test.
ERG: Electroretinogram reveals early involvement with attenuated b-wave amplitude
indicative of retinal pigment epithelium-photoreceptor dysfunction.
Nerve conduction studies: Demonstrate sensorimotor axonal neuropathy with reduced
velocities and compound muscle action potential amplitudes.
Brain MRI: Cerebellar atrophy and white matter changes supportive of clinical neuropathy
and cerebellar signs.
EBUS: Dilated cardiomyopathy evidenced on echocardiography with enlarged ventricular
chambers and reduced ejection fraction requiring cardiac MRI/biopsy correlation
occasionally.
Serum studies: Normal or minimally elevated liver enzymes, normal prothrombin time with
mildly prolonged APTT due to acquired von Willebrand disease. Very long chain fatty acid
analysis may detect accumulation secondarily.
Genetic testing: DNA sequencing to identify mutations in the PEX1, PEX2, PEX5, PEX6,
PEX10, PEX12, PEX13, PEX26 and AGPS genes confirms diagnosis when clinical features
and biochemical abnormalities are suggestive. Prenatal diagnosis is possible once the familial
mutation is identified.
Treatment and Management
There is currently no cure for Refsum disease, but an individualized multi-pronged treatment
approach targeting phytanic acid reduction, control of manifestations and prevention of
complications can provide effective long term control and improve prognosis significantly.
Diet: Strict essential fatty acid deficient (EFAD) diet avoids consumption of major phytanic
acid precursors derived from ruminant fats. Dairy, red meat, processed foods and
supplements containing phytol, pristanic acid or phytanic acid need lifelong restriction. While
not lowering stored tissue levels directly, this halts further input into circulation.
Phytanic acid lowering: Plasmapheresis or low density lipoprotein (LDL) apheresis removes
circulating phytanic acid every 2-4 weeks. This remains the primary specific therapy
reducing symptoms when initiated early. Alternative regimes include cholestyramine, an oral
anion exchange resin that binds phytanic acid in the gut facilitating fecal elimination.
Supportive care: Physiotherapy helps maintain mobility, occupational therapy aids daily
functioning. Speech therapy aids dysarthria. Orthotics support limbs.
Neuropathy: Gabapentin, pregabalin provide pain relief and improve sleep. IVIG may offer
stabilization in some.
Retinopathy: Antioxidant supplementation, protective sunglasses minimize advancement.
Vitamin A can supplement retinal function loss.
Cardiomyopathy: Standard heart failure medications, ICD placement if indicated. ACE
inhibitors reduce risk of decline even in mild forms.
Ataxia: Physical and occupational therapy helps balance, coordination.
Bleeding: Desmopressin, platelet transfusion as needed for invasive procedures to prevent
hemorrhage in advanced stages with coagulopathy.
Liver transplantation: Considered in rare severe early onset cases with persistent elevations
despite standard therapies in order to halt progressive neuronal damage due to phytanic acid
given its deposition in the brain. Outcomes have been mixed with limited long term follow up
available currently.
Multidisciplinary care involving metabolic disease specialists, neurologists,
ophthalmologists, cardiologists, hematologists, genetic counselors etc. provides optimal
lifelong management. Prompt initiation of specific therapies especially dietary changes
improves symptom control, functional status and long term prognosis for most Refsum
patients.
Prognosis
If untreated, Refsum disease is ultimately fatal affecting multiple organ systems. Historical
untreated or late treated cohorts demonstrated median survival of 35-40 years marked by
progressive neuropathy, cerebellar dysfunction leading to immobility, debilitating
cardiomyopathy, visual loss and bleeding complications.
However, outlook has transformed significantly with current specialized management
approaches. Prognosis depends upon age at which specific therapy is started, choice of
therapy utilized and individual disease severity. Early dietary modifications along with
plasmapheresis/LDL apheresis when commenced in a less symptomatic young adult appears
to halt progression arresting stored phytanic acid levels and associated complications.
Majority treated patients survive beyond 6th decade with meaningful quality of life
maintained. Neuropathy stabilizes leaving residual deficits. Vision and heart function
stabilize or improve in some. Mortality has reduced to <10% now often secondary to
arrhythmia, heart failure or thromboembolic disease if advanced. Prompt diagnosis and
lifelong multidisciplinary care under specialized metabolic centers has optimized outcomes
transforming Refsum disease from a uniformly fatal to now a manageable chronic disorder
for the majority. With ongoing research into pathogenesis, newer therapeutic targets like gene
therapy hold promise for a cure or disease modification in future.
Conclusion
In summary, Refsum disease is an extremely rare inherited disorder of peroxisomal phytanic
acid metabolism categorized under the group of peroxisomal biogenesis disorders. It
classically presents with a characteristic triad of progressive sensory motor neuropathy,
retinopathy and cardiomyopathy affecting multiple systems over the decades. Advancements
in our understanding of its genetic defects and pathophysiological mechanisms have greatly
facilitated early diagnosis through demonstration of elevated plasma and tissue phytanic acid
levels. An individually tailored multi-pronged management strategy focusing on phytanic
acid lowering through restricted diets, plasmapheresis and supportive care aims to stabilize
neurological, ocular and cardiac involvement thereby improving long term functional status
and survival. Earlier institution of specific therapies especially in less symptomatic phases
appears paramount for optimal outcomes thereby transforming previous dismal prognoses.
With continued research initiatives, more definitive and curative interventions for this
complex metabolic disorder may emerge in future.
Refsum disease is an extremely rare autosomal recessive genetic disorder belonging to the
group of peroxisomal biogenesis disorders. It is characterized by abnormal accumulation of
certain fatty substances called phytanic acid within the body's cells and tissues due to
impaired peroxisomal function. This builds up primarily in the nerves, blood vessels, and
retina resulting in a characteristic pattern of multi-system neurologic, cardiac and ocular
involvement. If left untreated, Refsum disease can lead to significant morbidity and even
mortality. However, early suspicion aided by diagnostic testing and specialized therapies
targeting phytanic acid reduction offers hope for improved long term prognosis. This paper
aims to provide a comprehensive overview of Refsum disease covering etiology, clinical
manifestations, diagnosis, management approaches and prognosis.
Genetics and Pathogenesis
Refsum disease arises due to mutations affecting genes encoding peroxisomal membrane or
matrix proteins critical for normal peroxisomal function and assembly. Specifically,
mutations in the PEX1, PEX2, PEX5, PEX6, PEX10, PEX12, PEX13, PEX26 and AGPS
genes which map to chromosomes 1p32, 11q12 and 2p13 have been implicated in Refsum
disease. Peroxisomes are subcellular organelles responsible for various metabolic reactions
including breakdown (catabolism) of very long chain fatty acids, bile acid intermediates and
polyunsaturated fatty acids like phytanic acid derived from ruminant animal fats and dairy
products.
In Refsum disease, dysfunction of the peroxisomal import receptor protein PEX5 due to
mutations prevents transport of catalase and other matrix enzymes into the peroxisome lumen
necessary for phytanic acid α-oxidation. This results in impaired phytanic acid catabolism
and its intracellular accumulation especially within the nervous system, blood vessels and
retina over decades. Phytanic acid is a branched chain saturated fatty acid which incorporates
within membrane phospholipids to cause structural and functional abnormalities. It also
exerts toxic effects by activating oxidative and endoplasmic reticulum stress pathways
inducing inflammatory cytokines and cell death if levels rise sufficiently. Accumulation of
phytanic acid and its lipid-derived metabolites are directly responsible for the multi-systemic
clinical manifestations seen in Refsum disease patients over time.
Clinical Features
The hallmark clinical triad in Refsum disease includes a progressive sensory motor peripheral
neuropathy, retinal degeneration causing night blindness and visual impairment and cardiac
abnormalities. Other associated features include anosmia, hearing loss, cerebellar ataxia,
skeletal abnormalities and coagulopathy.
Neuropathy: Diffuse sensory motor peripheral neuropathy commonly heralds illness onset in
the teenage years with numbness and paresthesias beginning distally in the lower extremities
and later involving hands. Progression results in severe sensory loss, variable degrees of
weakness, muscle wasting and impaired proprioception. Symptoms are often amplified by
cold exposure.
Retinopathy: Bilateral pigmentary retinopathy manifests as an early night blindness followed
by tunnel vision and progressive loss of peripheral vision. Fundus examination demonstrates
bone spicule pigment clumping in the retina and attenuation of retinal arterioles.
Cardiomyopathy: Dilated cardiomyopathy with impaired systolic function appears in adult
illness stages prompting congestive heart failure, arrhythmias and thromboembolism risk.
Cerebellar ataxia: Limb and gait ataxia arise secondarily from neuropathy and cerebellar
involvement evidenced clinically or on neuroimaging as cerebellar atrophy.
Anosmia: Loss of sense of smell affects up to 90% due to olfactory bulb degeneration.
Hearing loss: Sensorineural deafness develops later due to cochlear involvement.
Skeletal abnormalities: Epiphyseal dysplasia of long bones and vertebrae can occur with limb
deformities.
Coagulopathy: Platelet dysfunction, acquired von Willebrand disease and bleeding tendency
get manifested in advanced stages.
Constitutional symptoms: Non-specific complaints like fatigue, anorexia and weight loss
accompany severe multi-organ involvement.
Diagnosis
The presence of a characteristic clinical triad coupled with manifestations of multi-system
involvement should raise suspicion for Refsum disease even in the absence of family history
due to its rarity and genetic heterogeneity. Diagnosis relies on demonstrating elevated
phytanic acid levels in plasma or cultured skin fibroblasts along with exclusion of other
peroxisomal or lipid storage disorders.
Plasma phytanic acid: Elevated >2-3mg/dL in healthy individuals (<1mg/dL). Levels
progressively rise with advancing age and correlate with disease severity. A normal level
does not necessarily exclude the diagnosis though.
Skin fibroblast phytanic acid: Incubation with [3H]phytanic acid to show impaired β-
oxidation and accumulation within cells compared to normal fibroblasts serves as a highly
sensitive and specific diagnostic test.
ERG: Electroretinogram reveals early involvement with attenuated b-wave amplitude
indicative of retinal pigment epithelium-photoreceptor dysfunction.
Nerve conduction studies: Demonstrate sensorimotor axonal neuropathy with reduced
velocities and compound muscle action potential amplitudes.
Brain MRI: Cerebellar atrophy and white matter changes supportive of clinical neuropathy
and cerebellar signs.
EBUS: Dilated cardiomyopathy evidenced on echocardiography with enlarged ventricular
chambers and reduced ejection fraction requiring cardiac MRI/biopsy correlation
occasionally.
Serum studies: Normal or minimally elevated liver enzymes, normal prothrombin time with
mildly prolonged APTT due to acquired von Willebrand disease. Very long chain fatty acid
analysis may detect accumulation secondarily.
Genetic testing: DNA sequencing to identify mutations in the PEX1, PEX2, PEX5, PEX6,
PEX10, PEX12, PEX13, PEX26 and AGPS genes confirms diagnosis when clinical features
and biochemical abnormalities are suggestive. Prenatal diagnosis is possible once the familial
mutation is identified.
Treatment and Management
There is currently no cure for Refsum disease, but an individualized multi-pronged treatment
approach targeting phytanic acid reduction, control of manifestations and prevention of
complications can provide effective long term control and improve prognosis significantly.
Diet: Strict essential fatty acid deficient (EFAD) diet avoids consumption of major phytanic
acid precursors derived from ruminant fats. Dairy, red meat, processed foods and
supplements containing phytol, pristanic acid or phytanic acid need lifelong restriction. While
not lowering stored tissue levels directly, this halts further input into circulation.
Phytanic acid lowering: Plasmapheresis or low density lipoprotein (LDL) apheresis removes
circulating phytanic acid every 2-4 weeks. This remains the primary specific therapy
reducing symptoms when initiated early. Alternative regimes include cholestyramine, an oral
anion exchange resin that binds phytanic acid in the gut facilitating fecal elimination.
Supportive care: Physiotherapy helps maintain mobility, occupational therapy aids daily
functioning. Speech therapy aids dysarthria. Orthotics support limbs.
Neuropathy: Gabapentin, pregabalin provide pain relief and improve sleep. IVIG may offer
stabilization in some.
Retinopathy: Antioxidant supplementation, protective sunglasses minimize advancement.
Vitamin A can supplement retinal function loss.
Cardiomyopathy: Standard heart failure medications, ICD placement if indicated. ACE
inhibitors reduce risk of decline even in mild forms.
Ataxia: Physical and occupational therapy helps balance, coordination.
Bleeding: Desmopressin, platelet transfusion as needed for invasive procedures to prevent
hemorrhage in advanced stages with coagulopathy.
Liver transplantation: Considered in rare severe early onset cases with persistent elevations
despite standard therapies in order to halt progressive neuronal damage due to phytanic acid
given its deposition in the brain. Outcomes have been mixed with limited long term follow up
available currently.
Multidisciplinary care involving metabolic disease specialists, neurologists,
ophthalmologists, cardiologists, hematologists, genetic counselors etc. provides optimal
lifelong management. Prompt initiation of specific therapies especially dietary changes
improves symptom control, functional status and long term prognosis for most Refsum
patients.
Prognosis
If untreated, Refsum disease is ultimately fatal affecting multiple organ systems. Historical
untreated or late treated cohorts demonstrated median survival of 35-40 years marked by
progressive neuropathy, cerebellar dysfunction leading to immobility, debilitating
cardiomyopathy, visual loss and bleeding complications.
However, outlook has transformed significantly with current specialized management
approaches. Prognosis depends upon age at which specific therapy is started, choice of
therapy utilized and individual disease severity. Early dietary modifications along with
plasmapheresis/LDL apheresis when commenced in a less symptomatic young adult appears
to halt progression arresting stored phytanic acid levels and associated complications.
Majority treated patients survive beyond 6th decade with meaningful quality of life
maintained. Neuropathy stabilizes leaving residual deficits. Vision and heart function
stabilize or improve in some. Mortality has reduced to <10% now often secondary to
arrhythmia, heart failure or thromboembolic disease if advanced. Prompt diagnosis and
lifelong multidisciplinary care under specialized metabolic centers has optimized outcomes
transforming Refsum disease from a uniformly fatal to now a manageable chronic disorder
for the majority. With ongoing research into pathogenesis, newer therapeutic targets like gene
therapy hold promise for a cure or disease modification in future.
Conclusion
In summary, Refsum disease is an extremely rare inherited disorder of peroxisomal phytanic
acid metabolism categorized under the group of peroxisomal biogenesis disorders. It
classically presents with a characteristic triad of progressive sensory motor neuropathy,
retinopathy and cardiomyopathy affecting multiple systems over the decades. Advancements
in our understanding of its genetic defects and pathophysiological mechanisms have greatly
facilitated early diagnosis through demonstration of elevated plasma and tissue phytanic acid
levels. An individually tailored multi-pronged management strategy focusing on phytanic
acid lowering through restricted diets, plasmapheresis and supportive care aims to stabilize
neurological, ocular and cardiac involvement thereby improving long term functional status
and survival. Earlier institution of specific therapies especially in less symptomatic phases
appears paramount for optimal outcomes thereby transforming previous dismal prognoses.
With continued research initiatives, more definitive and curative interventions for this
complex metabolic disorder may emerge in future.
Refsum disease is an extremely rare autosomal recessive genetic disorder belonging to the
group of peroxisomal biogenesis disorders. It is characterized by abnormal accumulation of
certain fatty substances called phytanic acid within the body's cells and tissues due to
impaired peroxisomal function. This builds up primarily in the nerves, blood vessels, and
retina resulting in a characteristic pattern of multi-system neurologic, cardiac and ocular
involvement. If left untreated, Refsum disease can lead to significant morbidity and even
mortality. However, early suspicion aided by diagnostic testing and specialized therapies
targeting phytanic acid reduction offers hope for improved long term prognosis. This paper
aims to provide a comprehensive overview of Refsum disease covering etiology, clinical
manifestations, diagnosis, management approaches and prognosis.
Genetics and Pathogenesis
Refsum disease arises due to mutations affecting genes encoding peroxisomal membrane or
matrix proteins critical for normal peroxisomal function and assembly. Specifically,
mutations in the PEX1, PEX2, PEX5, PEX6, PEX10, PEX12, PEX13, PEX26 and AGPS
genes which map to chromosomes 1p32, 11q12 and 2p13 have been implicated in Refsum
disease. Peroxisomes are subcellular organelles responsible for various metabolic reactions
including breakdown (catabolism) of very long chain fatty acids, bile acid intermediates and
polyunsaturated fatty acids like phytanic acid derived from ruminant animal fats and dairy
products.
In Refsum disease, dysfunction of the peroxisomal import receptor protein PEX5 due to
mutations prevents transport of catalase and other matrix enzymes into the peroxisome lumen
necessary for phytanic acid α-oxidation. This results in impaired phytanic acid catabolism
and its intracellular accumulation especially within the nervous system, blood vessels and
retina over decades. Phytanic acid is a branched chain saturated fatty acid which incorporates
within membrane phospholipids to cause structural and functional abnormalities. It also
exerts toxic effects by activating oxidative and endoplasmic reticulum stress pathways
inducing inflammatory cytokines and cell death if levels rise sufficiently. Accumulation of
phytanic acid and its lipid-derived metabolites are directly responsible for the multi-systemic
clinical manifestations seen in Refsum disease patients over time.
Clinical Features
The hallmark clinical triad in Refsum disease includes a progressive sensory motor peripheral
neuropathy, retinal degeneration causing night blindness and visual impairment and cardiac
abnormalities. Other associated features include anosmia, hearing loss, cerebellar ataxia,
skeletal abnormalities and coagulopathy.
Neuropathy: Diffuse sensory motor peripheral neuropathy commonly heralds illness onset in
the teenage years with numbness and paresthesias beginning distally in the lower extremities
and later involving hands. Progression results in severe sensory loss, variable degrees of
weakness, muscle wasting and impaired proprioception. Symptoms are often amplified by
cold exposure.
Retinopathy: Bilateral pigmentary retinopathy manifests as an early night blindness followed
by tunnel vision and progressive loss of peripheral vision. Fundus examination demonstrates
bone spicule pigment clumping in the retina and attenuation of retinal arterioles.
Cardiomyopathy: Dilated cardiomyopathy with impaired systolic function appears in adult
illness stages prompting congestive heart failure, arrhythmias and thromboembolism risk.
Cerebellar ataxia: Limb and gait ataxia arise secondarily from neuropathy and cerebellar
involvement evidenced clinically or on neuroimaging as cerebellar atrophy.
Anosmia: Loss of sense of smell affects up to 90% due to olfactory bulb degeneration.
Hearing loss: Sensorineural deafness develops later due to cochlear involvement.
Skeletal abnormalities: Epiphyseal dysplasia of long bones and vertebrae can occur with limb
deformities.
Coagulopathy: Platelet dysfunction, acquired von Willebrand disease and bleeding tendency
get manifested in advanced stages.
Constitutional symptoms: Non-specific complaints like fatigue, anorexia and weight loss
accompany severe multi-organ involvement.
Diagnosis
The presence of a characteristic clinical triad coupled with manifestations of multi-system
involvement should raise suspicion for Refsum disease even in the absence of family history
due to its rarity and genetic heterogeneity. Diagnosis relies on demonstrating elevated
phytanic acid levels in plasma or cultured skin fibroblasts along with exclusion of other
peroxisomal or lipid storage disorders.
Plasma phytanic acid: Elevated >2-3mg/dL in healthy individuals (<1mg/dL). Levels
progressively rise with advancing age and correlate with disease severity. A normal level
does not necessarily exclude the diagnosis though.
Skin fibroblast phytanic acid: Incubation with [3H]phytanic acid to show impaired β-
oxidation and accumulation within cells compared to normal fibroblasts serves as a highly
sensitive and specific diagnostic test.
ERG: Electroretinogram reveals early involvement with attenuated b-wave amplitude
indicative of retinal pigment epithelium-photoreceptor dysfunction.
Nerve conduction studies: Demonstrate sensorimotor axonal neuropathy with reduced
velocities and compound muscle action potential amplitudes.
Brain MRI: Cerebellar atrophy and white matter changes supportive of clinical neuropathy
and cerebellar signs.
EBUS: Dilated cardiomyopathy evidenced on echocardiography with enlarged ventricular
chambers and reduced ejection fraction requiring cardiac MRI/biopsy correlation
occasionally.
Serum studies: Normal or minimally elevated liver enzymes, normal prothrombin time with
mildly prolonged APTT due to acquired von Willebrand disease. Very long chain fatty acid
analysis may detect accumulation secondarily.
Genetic testing: DNA sequencing to identify mutations in the PEX1, PEX2, PEX5, PEX6,
PEX10, PEX12, PEX13, PEX26 and AGPS genes confirms diagnosis when clinical features
and biochemical abnormalities are suggestive. Prenatal diagnosis is possible once the familial
mutation is identified.
Treatment and Management
There is currently no cure for Refsum disease, but an individualized multi-pronged treatment
approach targeting phytanic acid reduction, control of manifestations and prevention of
complications can provide effective long term control and improve prognosis significantly.
Diet: Strict essential fatty acid deficient (EFAD) diet avoids consumption of major phytanic
acid precursors derived from ruminant fats. Dairy, red meat, processed foods and
supplements containing phytol, pristanic acid or phytanic acid need lifelong restriction. While
not lowering stored tissue levels directly, this halts further input into circulation.
Phytanic acid lowering: Plasmapheresis or low density lipoprotein (LDL) apheresis removes
circulating phytanic acid every 2-4 weeks. This remains the primary specific therapy
reducing symptoms when initiated early. Alternative regimes include cholestyramine, an oral
anion exchange resin that binds phytanic acid in the gut facilitating fecal elimination.
Supportive care: Physiotherapy helps maintain mobility, occupational therapy aids daily
functioning. Speech therapy aids dysarthria. Orthotics support limbs.
Neuropathy: Gabapentin, pregabalin provide pain relief and improve sleep. IVIG may offer
stabilization in some.
Retinopathy: Antioxidant supplementation, protective sunglasses minimize advancement.
Vitamin A can supplement retinal function loss.
Cardiomyopathy: Standard heart failure medications, ICD placement if indicated. ACE
inhibitors reduce risk of decline even in mild forms.
Ataxia: Physical and occupational therapy helps balance, coordination.
Bleeding: Desmopressin, platelet transfusion as needed for invasive procedures to prevent
hemorrhage in advanced stages with coagulopathy.
Liver transplantation: Considered in rare severe early onset cases with persistent elevations
despite standard therapies in order to halt progressive neuronal damage due to phytanic acid
given its deposition in the brain. Outcomes have been mixed with limited long term follow up
available currently.
Multidisciplinary care involving metabolic disease specialists, neurologists,
ophthalmologists, cardiologists, hematologists, genetic counselors etc. provides optimal
lifelong management. Prompt initiation of specific therapies especially dietary changes
improves symptom control, functional status and long term prognosis for most Refsum
patients.
Prognosis
If untreated, Refsum disease is ultimately fatal affecting multiple organ systems. Historical
untreated or late treated cohorts demonstrated median survival of 35-40 years marked by
progressive neuropathy, cerebellar dysfunction leading to immobility, debilitating
cardiomyopathy, visual loss and bleeding complications.
However, outlook has transformed significantly with current specialized management
approaches. Prognosis depends upon age at which specific therapy is started, choice of
therapy utilized and individual disease severity. Early dietary modifications along with
plasmapheresis/LDL apheresis when commenced in a less symptomatic young adult appears
to halt progression arresting stored phytanic acid levels and associated complications.
Majority treated patients survive beyond 6th decade with meaningful quality of life
maintained. Neuropathy stabilizes leaving residual deficits. Vision and heart function
stabilize or improve in some. Mortality has reduced to <10% now often secondary to
arrhythmia, heart failure or thromboembolic disease if advanced. Prompt diagnosis and
lifelong multidisciplinary care under specialized metabolic centers has optimized outcomes
transforming Refsum disease from a uniformly fatal to now a manageable chronic disorder
for the majority. With ongoing research into pathogenesis, newer therapeutic targets like gene
therapy hold promise for a cure or disease modification in future.
Conclusion
In summary, Refsum disease is an extremely rare inherited disorder of peroxisomal phytanic
acid metabolism categorized under the group of peroxisomal biogenesis disorders. It
classically presents with a characteristic triad of progressive sensory motor neuropathy,
retinopathy and cardiomyopathy affecting multiple systems over the decades. Advancements
in our understanding of its genetic defects and pathophysiological mechanisms have greatly
facilitated early diagnosis through demonstration of elevated plasma and tissue phytanic acid
levels. An individually tailored multi-pronged management strategy focusing on phytanic
acid lowering through restricted diets, plasmapheresis and supportive care aims to stabilize
neurological, ocular and cardiac involvement thereby improving long term functional status
and survival. Earlier institution of specific therapies especially in less symptomatic phases
appears paramount for optimal outcomes thereby transforming previous dismal prognoses.
With continued research initiatives, more definitive and curative interventions for this
complex metabolic disorder may emerge in future.
Refsum disease is an extremely rare autosomal recessive genetic disorder belonging to the
group of peroxisomal biogenesis disorders. It is characterized by abnormal accumulation of
certain fatty substances called phytanic acid within the body's cells and tissues due to
impaired peroxisomal function. This builds up primarily in the nerves, blood vessels, and
retina resulting in a characteristic pattern of multi-system neurologic, cardiac and ocular
involvement. If left untreated, Refsum disease can lead to significant morbidity and even
mortality. However, early suspicion aided by diagnostic testing and specialized therapies
targeting phytanic acid reduction offers hope for improved long term prognosis. This paper
aims to provide a comprehensive overview of Refsum disease covering etiology, clinical
manifestations, diagnosis, management approaches and prognosis.
Genetics and Pathogenesis
Refsum disease arises due to mutations affecting genes encoding peroxisomal membrane or
matrix proteins critical for normal peroxisomal function and assembly. Specifically,
mutations in the PEX1, PEX2, PEX5, PEX6, PEX10, PEX12, PEX13, PEX26 and AGPS
genes which map to chromosomes 1p32, 11q12 and 2p13 have been implicated in Refsum
disease. Peroxisomes are subcellular organelles responsible for various metabolic reactions
including breakdown (catabolism) of very long chain fatty acids, bile acid intermediates and
polyunsaturated fatty acids like phytanic acid derived from ruminant animal fats and dairy
products.
In Refsum disease, dysfunction of the peroxisomal import receptor protein PEX5 due to
mutations prevents transport of catalase and other matrix enzymes into the peroxisome lumen
necessary for phytanic acid α-oxidation. This results in impaired phytanic acid catabolism
and its intracellular accumulation especially within the nervous system, blood vessels and
retina over decades. Phytanic acid is a branched chain saturated fatty acid which incorporates
within membrane phospholipids to cause structural and functional abnormalities. It also
exerts toxic effects by activating oxidative and endoplasmic reticulum stress pathways
inducing inflammatory cytokines and cell death if levels rise sufficiently. Accumulation of
phytanic acid and its lipid-derived metabolites are directly responsible for the multi-systemic
clinical manifestations seen in Refsum disease patients over time.
Clinical Features
The hallmark clinical triad in Refsum disease includes a progressive sensory motor peripheral
neuropathy, retinal degeneration causing night blindness and visual impairment and cardiac
abnormalities. Other associated features include anosmia, hearing loss, cerebellar ataxia,
skeletal abnormalities and coagulopathy.
Neuropathy: Diffuse sensory motor peripheral neuropathy commonly heralds illness onset in
the teenage years with numbness and paresthesias beginning distally in the lower extremities
and later involving hands. Progression results in severe sensory loss, variable degrees of
weakness, muscle wasting and impaired proprioception. Symptoms are often amplified by
cold exposure.
Retinopathy: Bilateral pigmentary retinopathy manifests as an early night blindness followed
by tunnel vision and progressive loss of peripheral vision. Fundus examination demonstrates
bone spicule pigment clumping in the retina and attenuation of retinal arterioles.
Cardiomyopathy: Dilated cardiomyopathy with impaired systolic function appears in adult
illness stages prompting congestive heart failure, arrhythmias and thromboembolism risk.
Cerebellar ataxia: Limb and gait ataxia arise secondarily from neuropathy and cerebellar
involvement evidenced clinically or on neuroimaging as cerebellar atrophy.
Anosmia: Loss of sense of smell affects up to 90% due to olfactory bulb degeneration.
Hearing loss: Sensorineural deafness develops later due to cochlear involvement.
Skeletal abnormalities: Epiphyseal dysplasia of long bones and vertebrae can occur with limb
deformities.
Coagulopathy: Platelet dysfunction, acquired von Willebrand disease and bleeding tendency
get manifested in advanced stages.
Constitutional symptoms: Non-specific complaints like fatigue, anorexia and weight loss
accompany severe multi-organ involvement.
Diagnosis
The presence of a characteristic clinical triad coupled with manifestations of multi-system
involvement should raise suspicion for Refsum disease even in the absence of family history
due to its rarity and genetic heterogeneity. Diagnosis relies on demonstrating elevated
phytanic acid levels in plasma or cultured skin fibroblasts along with exclusion of other
peroxisomal or lipid storage disorders.
Plasma phytanic acid: Elevated >2-3mg/dL in healthy individuals (<1mg/dL). Levels
progressively rise with advancing age and correlate with disease severity. A normal level
does not necessarily exclude the diagnosis though.
Skin fibroblast phytanic acid: Incubation with [3H]phytanic acid to show impaired β-
oxidation and accumulation within cells compared to normal fibroblasts serves as a highly
sensitive and specific diagnostic test.
ERG: Electroretinogram reveals early involvement with attenuated b-wave amplitude
indicative of retinal pigment epithelium-photoreceptor dysfunction.
Nerve conduction studies: Demonstrate sensorimotor axonal neuropathy with reduced
velocities and compound muscle action potential amplitudes.
Brain MRI: Cerebellar atrophy and white matter changes supportive of clinical neuropathy
and cerebellar signs.
EBUS: Dilated cardiomyopathy evidenced on echocardiography with enlarged ventricular
chambers and reduced ejection fraction requiring cardiac MRI/biopsy correlation
occasionally.
Serum studies: Normal or minimally elevated liver enzymes, normal prothrombin time with
mildly prolonged APTT due to acquired von Willebrand disease. Very long chain fatty acid
analysis may detect accumulation secondarily.
Genetic testing: DNA sequencing to identify mutations in the PEX1, PEX2, PEX5, PEX6,
PEX10, PEX12, PEX13, PEX26 and AGPS genes confirms diagnosis when clinical features
and biochemical abnormalities are suggestive. Prenatal diagnosis is possible once the familial
mutation is identified.
Treatment and Management
There is currently no cure for Refsum disease, but an individualized multi-pronged treatment
approach targeting phytanic acid reduction, control of manifestations and prevention of
complications can provide effective long term control and improve prognosis significantly.
Diet: Strict essential fatty acid deficient (EFAD) diet avoids consumption of major phytanic
acid precursors derived from ruminant fats. Dairy, red meat, processed foods and
supplements containing phytol, pristanic acid or phytanic acid need lifelong restriction. While
not lowering stored tissue levels directly, this halts further input into circulation.
Phytanic acid lowering: Plasmapheresis or low density lipoprotein (LDL) apheresis removes
circulating phytanic acid every 2-4 weeks. This remains the primary specific therapy
reducing symptoms when initiated early. Alternative regimes include cholestyramine, an oral
anion exchange resin that binds phytanic acid in the gut facilitating fecal elimination.
Supportive care: Physiotherapy helps maintain mobility, occupational therapy aids daily
functioning. Speech therapy aids dysarthria. Orthotics support limbs.
Neuropathy: Gabapentin, pregabalin provide pain relief and improve sleep. IVIG may offer
stabilization in some.
Retinopathy: Antioxidant supplementation, protective sunglasses minimize advancement.
Vitamin A can supplement retinal function loss.
Cardiomyopathy: Standard heart failure medications, ICD placement if indicated. ACE
inhibitors reduce risk of decline even in mild forms.
Ataxia: Physical and occupational therapy helps balance, coordination.
Bleeding: Desmopressin, platelet transfusion as needed for invasive procedures to prevent
hemorrhage in advanced stages with coagulopathy.
Liver transplantation: Considered in rare severe early onset cases with persistent elevations
despite standard therapies in order to halt progressive neuronal damage due to phytanic acid
given its deposition in the brain. Outcomes have been mixed with limited long term follow up
available currently.
Multidisciplinary care involving metabolic disease specialists, neurologists,
ophthalmologists, cardiologists, hematologists, genetic counselors etc. provides optimal
lifelong management. Prompt initiation of specific therapies especially dietary changes
improves symptom control, functional status and long term prognosis for most Refsum
patients.
Prognosis
If untreated, Refsum disease is ultimately fatal affecting multiple organ systems. Historical
untreated or late treated cohorts demonstrated median survival of 35-40 years marked by
progressive neuropathy, cerebellar dysfunction leading to immobility, debilitating
cardiomyopathy, visual loss and bleeding complications.
However, outlook has transformed significantly with current specialized management
approaches. Prognosis depends upon age at which specific therapy is started, choice of
therapy utilized and individual disease severity. Early dietary modifications along with
plasmapheresis/LDL apheresis when commenced in a less symptomatic young adult appears
to halt progression arresting stored phytanic acid levels and associated complications.
Majority treated patients survive beyond 6th decade with meaningful quality of life
maintained. Neuropathy stabilizes leaving residual deficits. Vision and heart function
stabilize or improve in some. Mortality has reduced to <10% now often secondary to
arrhythmia, heart failure or thromboembolic disease if advanced. Prompt diagnosis and
lifelong multidisciplinary care under specialized metabolic centers has optimized outcomes
transforming Refsum disease from a uniformly fatal to now a manageable chronic disorder
for the majority. With ongoing research into pathogenesis, newer therapeutic targets like gene
therapy hold promise for a cure or disease modification in future.
Conclusion
In summary, Refsum disease is an extremely rare inherited disorder of peroxisomal phytanic
acid metabolism categorized under the group of peroxisomal biogenesis disorders. It
classically presents with a characteristic triad of progressive sensory motor neuropathy,
retinopathy and cardiomyopathy affecting multiple systems over the decades. Advancements
in our understanding of its genetic defects and pathophysiological mechanisms have greatly
facilitated early diagnosis through demonstration of elevated plasma and tissue phytanic acid
levels. An individually tailored multi-pronged management strategy focusing on phytanic
acid lowering through restricted diets, plasmapheresis and supportive care aims to stabilize
neurological, ocular and cardiac involvement thereby improving long term functional status
and survival. Earlier institution of specific therapies especially in less symptomatic phases
appears paramount for optimal outcomes thereby transforming previous dismal prognoses.
With continued research initiatives, more definitive and curative interventions for this
complex metabolic disorder may emerge in future.
Refsum disease is an extremely rare autosomal recessive genetic disorder belonging to the
group of peroxisomal biogenesis disorders. It is characterized by abnormal accumulation of
certain fatty substances called phytanic acid within the body's cells and tissues due to
impaired peroxisomal function. This builds up primarily in the nerves, blood vessels, and
retina resulting in a characteristic pattern of multi-system neurologic, cardiac and ocular
involvement. If left untreated, Refsum disease can lead to significant morbidity and even
mortality. However, early suspicion aided by diagnostic testing and specialized therapies
targeting phytanic acid reduction offers hope for improved long term prognosis. This paper
aims to provide a comprehensive overview of Refsum disease covering etiology, clinical
manifestations, diagnosis, management approaches and prognosis.
Genetics and Pathogenesis
Refsum disease arises due to mutations affecting genes encoding peroxisomal membrane or
matrix proteins critical for normal peroxisomal function and assembly. Specifically,
mutations in the PEX1, PEX2, PEX5, PEX6, PEX10, PEX12, PEX13, PEX26 and AGPS
genes which map to chromosomes 1p32, 11q12 and 2p13 have been implicated in Refsum
disease. Peroxisomes are subcellular organelles responsible for various metabolic reactions
including breakdown (catabolism) of very long chain fatty acids, bile acid intermediates and
polyunsaturated fatty acids like phytanic acid derived from ruminant animal fats and dairy
products.
In Refsum disease, dysfunction of the peroxisomal import receptor protein PEX5 due to
mutations prevents transport of catalase and other matrix enzymes into the peroxisome lumen
necessary for phytanic acid α-oxidation. This results in impaired phytanic acid catabolism
and its intracellular accumulation especially within the nervous system, blood vessels and
retina over decades. Phytanic acid is a branched chain saturated fatty acid which incorporates
within membrane phospholipids to cause structural and functional abnormalities. It also
exerts toxic effects by activating oxidative and endoplasmic reticulum stress pathways
inducing inflammatory cytokines and cell death if levels rise sufficiently. Accumulation of
phytanic acid and its lipid-derived metabolites are directly responsible for the multi-systemic
clinical manifestations seen in Refsum disease patients over time.
Clinical Features
The hallmark clinical triad in Refsum disease includes a progressive sensory motor peripheral
neuropathy, retinal degeneration causing night blindness and visual impairment and cardiac
abnormalities. Other associated features include anosmia, hearing loss, cerebellar ataxia,
skeletal abnormalities and coagulopathy.
Neuropathy: Diffuse sensory motor peripheral neuropathy commonly heralds illness onset in
the teenage years with numbness and paresthesias beginning distally in the lower extremities
and later involving hands. Progression results in severe sensory loss, variable degrees of
weakness, muscle wasting and impaired proprioception. Symptoms are often amplified by
cold exposure.
Retinopathy: Bilateral pigmentary retinopathy manifests as an early night blindness followed
by tunnel vision and progressive loss of peripheral vision. Fundus examination demonstrates
bone spicule pigment clumping in the retina and attenuation of retinal arterioles.
Cardiomyopathy: Dilated cardiomyopathy with impaired systolic function appears in adult
illness stages prompting congestive heart failure, arrhythmias and thromboembolism risk.
Cerebellar ataxia: Limb and gait ataxia arise secondarily from neuropathy and cerebellar
involvement evidenced clinically or on neuroimaging as cerebellar atrophy.
Anosmia: Loss of sense of smell affects up to 90% due to olfactory bulb degeneration.
Hearing loss: Sensorineural deafness develops later due to cochlear involvement.
Skeletal abnormalities: Epiphyseal dysplasia of long bones and vertebrae can occur with limb
deformities.
Coagulopathy: Platelet dysfunction, acquired von Willebrand disease and bleeding tendency
get manifested in advanced stages.
Constitutional symptoms: Non-specific complaints like fatigue, anorexia and weight loss
accompany severe multi-organ involvement.
Diagnosis
The presence of a characteristic clinical triad coupled with manifestations of multi-system
involvement should raise suspicion for Refsum disease even in the absence of family history
due to its rarity and genetic heterogeneity. Diagnosis relies on demonstrating elevated
phytanic acid levels in plasma or cultured skin fibroblasts along with exclusion of other
peroxisomal or lipid storage disorders.
Plasma phytanic acid: Elevated >2-3mg/dL in healthy individuals (<1mg/dL). Levels
progressively rise with advancing age and correlate with disease severity. A normal level
does not necessarily exclude the diagnosis though.
Skin fibroblast phytanic acid: Incubation with [3H]phytanic acid to show impaired β-
oxidation and accumulation within cells compared to normal fibroblasts serves as a highly
sensitive and specific diagnostic test.
ERG: Electroretinogram reveals early involvement with attenuated b-wave amplitude
indicative of retinal pigment epithelium-photoreceptor dysfunction.
Nerve conduction studies: Demonstrate sensorimotor axonal neuropathy with reduced
velocities and compound muscle action potential amplitudes.
Brain MRI: Cerebellar atrophy and white matter changes supportive of clinical neuropathy
and cerebellar signs.
EBUS: Dilated cardiomyopathy evidenced on echocardiography with enlarged ventricular
chambers and reduced ejection fraction requiring cardiac MRI/biopsy correlation
occasionally.
Serum studies: Normal or minimally elevated liver enzymes, normal prothrombin time with
mildly prolonged APTT due to acquired von Willebrand disease. Very long chain fatty acid
analysis may detect accumulation secondarily.
Genetic testing: DNA sequencing to identify mutations in the PEX1, PEX2, PEX5, PEX6,
PEX10, PEX12, PEX13, PEX26 and AGPS genes confirms diagnosis when clinical features
and biochemical abnormalities are suggestive. Prenatal diagnosis is possible once the familial
mutation is identified.
Treatment and Management
There is currently no cure for Refsum disease, but an individualized multi-pronged treatment
approach targeting phytanic acid reduction, control of manifestations and prevention of
complications can provide effective long term control and improve prognosis significantly.
Diet: Strict essential fatty acid deficient (EFAD) diet avoids consumption of major phytanic
acid precursors derived from ruminant fats. Dairy, red meat, processed foods and
supplements containing phytol, pristanic acid or phytanic acid need lifelong restriction. While
not lowering stored tissue levels directly, this halts further input into circulation.
Phytanic acid lowering: Plasmapheresis or low density lipoprotein (LDL) apheresis removes
circulating phytanic acid every 2-4 weeks. This remains the primary specific therapy
reducing symptoms when initiated early. Alternative regimes include cholestyramine, an oral
anion exchange resin that binds phytanic acid in the gut facilitating fecal elimination.
Supportive care: Physiotherapy helps maintain mobility, occupational therapy aids daily
functioning. Speech therapy aids dysarthria. Orthotics support limbs.
Neuropathy: Gabapentin, pregabalin provide pain relief and improve sleep. IVIG may offer
stabilization in some.
Retinopathy: Antioxidant supplementation, protective sunglasses minimize advancement.
Vitamin A can supplement retinal function loss.
Cardiomyopathy: Standard heart failure medications, ICD placement if indicated. ACE
inhibitors reduce risk of decline even in mild forms.
Ataxia: Physical and occupational therapy helps balance, coordination.
Bleeding: Desmopressin, platelet transfusion as needed for invasive procedures to prevent
hemorrhage in advanced stages with coagulopathy.
Liver transplantation: Considered in rare severe early onset cases with persistent elevations
despite standard therapies in order to halt progressive neuronal damage due to phytanic acid
given its deposition in the brain. Outcomes have been mixed with limited long term follow up
available currently.
Multidisciplinary care involving metabolic disease specialists, neurologists,
ophthalmologists, cardiologists, hematologists, genetic counselors etc. provides optimal
lifelong management. Prompt initiation of specific therapies especially dietary changes
improves symptom control, functional status and long term prognosis for most Refsum
patients.
Prognosis
If untreated, Refsum disease is ultimately fatal affecting multiple organ systems. Historical
untreated or late treated cohorts demonstrated median survival of 35-40 years marked by
progressive neuropathy, cerebellar dysfunction leading to immobility, debilitating
cardiomyopathy, visual loss and bleeding complications.
However, outlook has transformed significantly with current specialized management
approaches. Prognosis depends upon age at which specific therapy is started, choice of
therapy utilized and individual disease severity. Early dietary modifications along with
plasmapheresis/LDL apheresis when commenced in a less symptomatic young adult appears
to halt progression arresting stored phytanic acid levels and associated complications.
Majority treated patients survive beyond 6th decade with meaningful quality of life
maintained. Neuropathy stabilizes leaving residual deficits. Vision and heart function
stabilize or improve in some. Mortality has reduced to <10% now often secondary to
arrhythmia, heart failure or thromboembolic disease if advanced. Prompt diagnosis and
lifelong multidisciplinary care under specialized metabolic centers has optimized outcomes
transforming Refsum disease from a uniformly fatal to now a manageable chronic disorder
for the majority. With ongoing research into pathogenesis, newer therapeutic targets like gene
therapy hold promise for a cure or disease modification in future.
Conclusion
In summary, Refsum disease is an extremely rare inherited disorder of peroxisomal phytanic
acid metabolism categorized under the group of peroxisomal biogenesis disorders. It
classically presents with a characteristic triad of progressive sensory motor neuropathy,
retinopathy and cardiomyopathy affecting multiple systems over the decades. Advancements
in our understanding of its genetic defects and pathophysiological mechanisms have greatly
facilitated early diagnosis through demonstration of elevated plasma and tissue phytanic acid
levels. An individually tailored multi-pronged management strategy focusing on phytanic
acid lowering through restricted diets, plasmapheresis and supportive care aims to stabilize
neurological, ocular and cardiac involvement thereby improving long term functional status
and survival. Earlier institution of specific therapies especially in less symptomatic phases
appears paramount for optimal outcomes thereby transforming previous dismal prognoses.
With continued research initiatives, more definitive and curative interventions for this
complex metabolic disorder may emerge in future.
Refsum disease is an extremely rare autosomal recessive genetic disorder belonging to the
group of peroxisomal biogenesis disorders. It is characterized by abnormal accumulation of
certain fatty substances called phytanic acid within the body's cells and tissues due to
impaired peroxisomal function. This builds up primarily in the nerves, blood vessels, and
retina resulting in a characteristic pattern of multi-system neurologic, cardiac and ocular
involvement. If left untreated, Refsum disease can lead to significant morbidity and even
mortality. However, early suspicion aided by diagnostic testing and specialized therapies
targeting phytanic acid reduction offers hope for improved long term prognosis. This paper
aims to provide a comprehensive overview of Refsum disease covering etiology, clinical
manifestations, diagnosis, management approaches and prognosis.
Genetics and Pathogenesis
Refsum disease arises due to mutations affecting genes encoding peroxisomal membrane or
matrix proteins critical for normal peroxisomal function and assembly. Specifically,
mutations in the PEX1, PEX2, PEX5, PEX6, PEX10, PEX12, PEX13, PEX26 and AGPS
genes which map to chromosomes 1p32, 11q12 and 2p13 have been implicated in Refsum
disease. Peroxisomes are subcellular organelles responsible for various metabolic reactions
including breakdown (catabolism) of very long chain fatty acids, bile acid intermediates and
polyunsaturated fatty acids like phytanic acid derived from ruminant animal fats and dairy
products.
In Refsum disease, dysfunction of the peroxisomal import receptor protein PEX5 due to
mutations prevents transport of catalase and other matrix enzymes into the peroxisome lumen
necessary for phytanic acid α-oxidation. This results in impaired phytanic acid catabolism
and its intracellular accumulation especially within the nervous system, blood vessels and
retina over decades. Phytanic acid is a branched chain saturated fatty acid which incorporates
within membrane phospholipids to cause structural and functional abnormalities. It also
exerts toxic effects by activating oxidative and endoplasmic reticulum stress pathways
inducing inflammatory cytokines and cell death if levels rise sufficiently. Accumulation of
phytanic acid and its lipid-derived metabolites are directly responsible for the multi-systemic
clinical manifestations seen in Refsum disease patients over time.
Clinical Features
The hallmark clinical triad in Refsum disease includes a progressive sensory motor peripheral
neuropathy, retinal degeneration causing night blindness and visual impairment and cardiac
abnormalities. Other associated features include anosmia, hearing loss, cerebellar ataxia,
skeletal abnormalities and coagulopathy.
Neuropathy: Diffuse sensory motor peripheral neuropathy commonly heralds illness onset in
the teenage years with numbness and paresthesias beginning distally in the lower extremities
and later involving hands. Progression results in severe sensory loss, variable degrees of
weakness, muscle wasting and impaired proprioception. Symptoms are often amplified by
cold exposure.
Retinopathy: Bilateral pigmentary retinopathy manifests as an early night blindness followed
by tunnel vision and progressive loss of peripheral vision. Fundus examination demonstrates
bone spicule pigment clumping in the retina and attenuation of retinal arterioles.
Cardiomyopathy: Dilated cardiomyopathy with impaired systolic function appears in adult
illness stages prompting congestive heart failure, arrhythmias and thromboembolism risk.
Cerebellar ataxia: Limb and gait ataxia arise secondarily from neuropathy and cerebellar
involvement evidenced clinically or on neuroimaging as cerebellar atrophy.
Anosmia: Loss of sense of smell affects up to 90% due to olfactory bulb degeneration.
Hearing loss: Sensorineural deafness develops later due to cochlear involvement.
Skeletal abnormalities: Epiphyseal dysplasia of long bones and vertebrae can occur with limb
deformities.
Coagulopathy: Platelet dysfunction, acquired von Willebrand disease and bleeding tendency
get manifested in advanced stages.
Constitutional symptoms: Non-specific complaints like fatigue, anorexia and weight loss
accompany severe multi-organ involvement.
Diagnosis
The presence of a characteristic clinical triad coupled with manifestations of multi-system
involvement should raise suspicion for Refsum disease even in the absence of family history
due to its rarity and genetic heterogeneity. Diagnosis relies on demonstrating elevated
phytanic acid levels in plasma or cultured skin fibroblasts along with exclusion of other
peroxisomal or lipid storage disorders.
Plasma phytanic acid: Elevated >2-3mg/dL in healthy individuals (<1mg/dL). Levels
progressively rise with advancing age and correlate with disease severity. A normal level
does not necessarily exclude the diagnosis though.
Skin fibroblast phytanic acid: Incubation with [3H]phytanic acid to show impaired β-
oxidation and accumulation within cells compared to normal fibroblasts serves as a highly
sensitive and specific diagnostic test.
ERG: Electroretinogram reveals early involvement with attenuated b-wave amplitude
indicative of retinal pigment epithelium-photoreceptor dysfunction.
Nerve conduction studies: Demonstrate sensorimotor axonal neuropathy with reduced
velocities and compound muscle action potential amplitudes.
Brain MRI: Cerebellar atrophy and white matter changes supportive of clinical neuropathy
and cerebellar signs.
EBUS: Dilated cardiomyopathy evidenced on echocardiography with enlarged ventricular
chambers and reduced ejection fraction requiring cardiac MRI/biopsy correlation
occasionally.
Serum studies: Normal or minimally elevated liver enzymes, normal prothrombin time with
mildly prolonged APTT due to acquired von Willebrand disease. Very long chain fatty acid
analysis may detect accumulation secondarily.
Genetic testing: DNA sequencing to identify mutations in the PEX1, PEX2, PEX5, PEX6,
PEX10, PEX12, PEX13, PEX26 and AGPS genes confirms diagnosis when clinical features
and biochemical abnormalities are suggestive. Prenatal diagnosis is possible once the familial
mutation is identified.
Treatment and Management
There is currently no cure for Refsum disease, but an individualized multi-pronged treatment
approach targeting phytanic acid reduction, control of manifestations and prevention of
complications can provide effective long term control and improve prognosis significantly.
Diet: Strict essential fatty acid deficient (EFAD) diet avoids consumption of major phytanic
acid precursors derived from ruminant fats. Dairy, red meat, processed foods and
supplements containing phytol, pristanic acid or phytanic acid need lifelong restriction. While
not lowering stored tissue levels directly, this halts further input into circulation.
Phytanic acid lowering: Plasmapheresis or low density lipoprotein (LDL) apheresis removes
circulating phytanic acid every 2-4 weeks. This remains the primary specific therapy
reducing symptoms when initiated early. Alternative regimes include cholestyramine, an oral
anion exchange resin that binds phytanic acid in the gut facilitating fecal elimination.
Supportive care: Physiotherapy helps maintain mobility, occupational therapy aids daily
functioning. Speech therapy aids dysarthria. Orthotics support limbs.
Neuropathy: Gabapentin, pregabalin provide pain relief and improve sleep. IVIG may offer
stabilization in some.
Retinopathy: Antioxidant supplementation, protective sunglasses minimize advancement.
Vitamin A can supplement retinal function loss.
Cardiomyopathy: Standard heart failure medications, ICD placement if indicated. ACE
inhibitors reduce risk of decline even in mild forms.
Ataxia: Physical and occupational therapy helps balance, coordination.
Bleeding: Desmopressin, platelet transfusion as needed for invasive procedures to prevent
hemorrhage in advanced stages with coagulopathy.
Liver transplantation: Considered in rare severe early onset cases with persistent elevations
despite standard therapies in order to halt progressive neuronal damage due to phytanic acid
given its deposition in the brain. Outcomes have been mixed with limited long term follow up
available currently.
Multidisciplinary care involving metabolic disease specialists, neurologists,
ophthalmologists, cardiologists, hematologists, genetic counselors etc. provides optimal
lifelong management. Prompt initiation of specific therapies especially dietary changes
improves symptom control, functional status and long term prognosis for most Refsum
patients.
Prognosis
If untreated, Refsum disease is ultimately fatal affecting multiple organ systems. Historical
untreated or late treated cohorts demonstrated median survival of 35-40 years marked by
progressive neuropathy, cerebellar dysfunction leading to immobility, debilitating
cardiomyopathy, visual loss and bleeding complications.
However, outlook has transformed significantly with current specialized management
approaches. Prognosis depends upon age at which specific therapy is started, choice of
therapy utilized and individual disease severity. Early dietary modifications along with
plasmapheresis/LDL apheresis when commenced in a less symptomatic young adult appears
to halt progression arresting stored phytanic acid levels and associated complications.
Majority treated patients survive beyond 6th decade with meaningful quality of life
maintained. Neuropathy stabilizes leaving residual deficits. Vision and heart function
stabilize or improve in some. Mortality has reduced to <10% now often secondary to
arrhythmia, heart failure or thromboembolic disease if advanced. Prompt diagnosis and
lifelong multidisciplinary care under specialized metabolic centers has optimized outcomes
transforming Refsum disease from a uniformly fatal to now a manageable chronic disorder
for the majority. With ongoing research into pathogenesis, newer therapeutic targets like gene
therapy hold promise for a cure or disease modification in future.
Conclusion
In summary, Refsum disease is an extremely rare inherited disorder of peroxisomal phytanic
acid metabolism categorized under the group of peroxisomal biogenesis disorders. It
classically presents with a characteristic triad of progressive sensory motor neuropathy,
retinopathy and cardiomyopathy affecting multiple systems over the decades. Advancements
in our understanding of its genetic defects and pathophysiological mechanisms have greatly
facilitated early diagnosis through demonstration of elevated plasma and tissue phytanic acid
levels. An individually tailored multi-pronged management strategy focusing on phytanic
acid lowering through restricted diets, plasmapheresis and supportive care aims to stabilize
neurological, ocular and cardiac involvement thereby improving long term functional status
and survival. Earlier institution of specific therapies especially in less symptomatic phases
appears paramount for optimal outcomes thereby transforming previous dismal prognoses.
With continued research initiatives, more definitive and curative interventions for this
complex metabolic disorder may emerge in future.
Refsum disease is an extremely rare autosomal recessive genetic disorder belonging to the
group of peroxisomal biogenesis disorders. It is characterized by abnormal accumulation of
certain fatty substances called phytanic acid within the body's cells and tissues due to
impaired peroxisomal function. This builds up primarily in the nerves, blood vessels, and
retina resulting in a characteristic pattern of multi-system neurologic, cardiac and ocular
involvement. If left untreated, Refsum disease can lead to significant morbidity and even
mortality. However, early suspicion aided by diagnostic testing and specialized therapies
targeting phytanic acid reduction offers hope for improved long term prognosis. This paper
aims to provide a comprehensive overview of Refsum disease covering etiology, clinical
manifestations, diagnosis, management approaches and prognosis.
Genetics and Pathogenesis
Refsum disease arises due to mutations affecting genes encoding peroxisomal membrane or
matrix proteins critical for normal peroxisomal function and assembly. Specifically,
mutations in the PEX1, PEX2, PEX5, PEX6, PEX10, PEX12, PEX13, PEX26 and AGPS
genes which map to chromosomes 1p32, 11q12 and 2p13 have been implicated in Refsum
disease. Peroxisomes are subcellular organelles responsible for various metabolic reactions
including breakdown (catabolism) of very long chain fatty acids, bile acid intermediates and
polyunsaturated fatty acids like phytanic acid derived from ruminant animal fats and dairy
products.
In Refsum disease, dysfunction of the peroxisomal import receptor protein PEX5 due to
mutations prevents transport of catalase and other matrix enzymes into the peroxisome lumen
necessary for phytanic acid α-oxidation. This results in impaired phytanic acid catabolism
and its intracellular accumulation especially within the nervous system, blood vessels and
retina over decades. Phytanic acid is a branched chain saturated fatty acid which incorporates
within membrane phospholipids to cause structural and functional abnormalities. It also
exerts toxic effects by activating oxidative and endoplasmic reticulum stress pathways
inducing inflammatory cytokines and cell death if levels rise sufficiently. Accumulation of
phytanic acid and its lipid-derived metabolites are directly responsible for the multi-systemic
clinical manifestations seen in Refsum disease patients over time.
Clinical Features
The hallmark clinical triad in Refsum disease includes a progressive sensory motor peripheral
neuropathy, retinal degeneration causing night blindness and visual impairment and cardiac
abnormalities. Other associated features include anosmia, hearing loss, cerebellar ataxia,
skeletal abnormalities and coagulopathy.
Neuropathy: Diffuse sensory motor peripheral neuropathy commonly heralds illness onset in
the teenage years with numbness and paresthesias beginning distally in the lower extremities
and later involving hands. Progression results in severe sensory loss, variable degrees of
weakness, muscle wasting and impaired proprioception. Symptoms are often amplified by
cold exposure.
Retinopathy: Bilateral pigmentary retinopathy manifests as an early night blindness followed
by tunnel vision and progressive loss of peripheral vision. Fundus examination demonstrates
bone spicule pigment clumping in the retina and attenuation of retinal arterioles.
Cardiomyopathy: Dilated cardiomyopathy with impaired systolic function appears in adult
illness stages prompting congestive heart failure, arrhythmias and thromboembolism risk.
Cerebellar ataxia: Limb and gait ataxia arise secondarily from neuropathy and cerebellar
involvement evidenced clinically or on neuroimaging as cerebellar atrophy.
Anosmia: Loss of sense of smell affects up to 90% due to olfactory bulb degeneration.
Hearing loss: Sensorineural deafness develops later due to cochlear involvement.
Skeletal abnormalities: Epiphyseal dysplasia of long bones and vertebrae can occur with limb
deformities.
Coagulopathy: Platelet dysfunction, acquired von Willebrand disease and bleeding tendency
get manifested in advanced stages.
Constitutional symptoms: Non-specific complaints like fatigue, anorexia and weight loss
accompany severe multi-organ involvement.
Diagnosis
The presence of a characteristic clinical triad coupled with manifestations of multi-system
involvement should raise suspicion for Refsum disease even in the absence of family history
due to its rarity and genetic heterogeneity. Diagnosis relies on demonstrating elevated
phytanic acid levels in plasma or cultured skin fibroblasts along with exclusion of other
peroxisomal or lipid storage disorders.
Plasma phytanic acid: Elevated >2-3mg/dL in healthy individuals (<1mg/dL). Levels
progressively rise with advancing age and correlate with disease severity. A normal level
does not necessarily exclude the diagnosis though.
Skin fibroblast phytanic acid: Incubation with [3H]phytanic acid to show impaired β-
oxidation and accumulation within cells compared to normal fibroblasts serves as a highly
sensitive and specific diagnostic test.
ERG: Electroretinogram reveals early involvement with attenuated b-wave amplitude
indicative of retinal pigment epithelium-photoreceptor dysfunction.
Nerve conduction studies: Demonstrate sensorimotor axonal neuropathy with reduced
velocities and compound muscle action potential amplitudes.
Brain MRI: Cerebellar atrophy and white matter changes supportive of clinical neuropathy
and cerebellar signs.
EBUS: Dilated cardiomyopathy evidenced on echocardiography with enlarged ventricular
chambers and reduced ejection fraction requiring cardiac MRI/biopsy correlation
occasionally.
Serum studies: Normal or minimally elevated liver enzymes, normal prothrombin time with
mildly prolonged APTT due to acquired von Willebrand disease. Very long chain fatty acid
analysis may detect accumulation secondarily.
Genetic testing: DNA sequencing to identify mutations in the PEX1, PEX2, PEX5, PEX6,
PEX10, PEX12, PEX13, PEX26 and AGPS genes confirms diagnosis when clinical features
and biochemical abnormalities are suggestive. Prenatal diagnosis is possible once the familial
mutation is identified.
Treatment and Management
There is currently no cure for Refsum disease, but an individualized multi-pronged treatment
approach targeting phytanic acid reduction, control of manifestations and prevention of
complications can provide effective long term control and improve prognosis significantly.
Diet: Strict essential fatty acid deficient (EFAD) diet avoids consumption of major phytanic
acid precursors derived from ruminant fats. Dairy, red meat, processed foods and
supplements containing phytol, pristanic acid or phytanic acid need lifelong restriction. While
not lowering stored tissue levels directly, this halts further input into circulation.
Phytanic acid lowering: Plasmapheresis or low density lipoprotein (LDL) apheresis removes
circulating phytanic acid every 2-4 weeks. This remains the primary specific therapy
reducing symptoms when initiated early. Alternative regimes include cholestyramine, an oral
anion exchange resin that binds phytanic acid in the gut facilitating fecal elimination.
Supportive care: Physiotherapy helps maintain mobility, occupational therapy aids daily
functioning. Speech therapy aids dysarthria. Orthotics support limbs.
Neuropathy: Gabapentin, pregabalin provide pain relief and improve sleep. IVIG may offer
stabilization in some.
Retinopathy: Antioxidant supplementation, protective sunglasses minimize advancement.
Vitamin A can supplement retinal function loss.
Cardiomyopathy: Standard heart failure medications, ICD placement if indicated. ACE
inhibitors reduce risk of decline even in mild forms.
Ataxia: Physical and occupational therapy helps balance, coordination.
Bleeding: Desmopressin, platelet transfusion as needed for invasive procedures to prevent
hemorrhage in advanced stages with coagulopathy.
Liver transplantation: Considered in rare severe early onset cases with persistent elevations
despite standard therapies in order to halt progressive neuronal damage due to phytanic acid
given its deposition in the brain. Outcomes have been mixed with limited long term follow up
available currently.
Multidisciplinary care involving metabolic disease specialists, neurologists,
ophthalmologists, cardiologists, hematologists, genetic counselors etc. provides optimal
lifelong management. Prompt initiation of specific therapies especially dietary changes
improves symptom control, functional status and long term prognosis for most Refsum
patients.
Prognosis
If untreated, Refsum disease is ultimately fatal affecting multiple organ systems. Historical
untreated or late treated cohorts demonstrated median survival of 35-40 years marked by
progressive neuropathy, cerebellar dysfunction leading to immobility, debilitating
cardiomyopathy, visual loss and bleeding complications.
However, outlook has transformed significantly with current specialized management
approaches. Prognosis depends upon age at which specific therapy is started, choice of
therapy utilized and individual disease severity. Early dietary modifications along with
plasmapheresis/LDL apheresis when commenced in a less symptomatic young adult appears
to halt progression arresting stored phytanic acid levels and associated complications.
Majority treated patients survive beyond 6th decade with meaningful quality of life
maintained. Neuropathy stabilizes leaving residual deficits. Vision and heart function
stabilize or improve in some. Mortality has reduced to <10% now often secondary to
arrhythmia, heart failure or thromboembolic disease if advanced. Prompt diagnosis and
lifelong multidisciplinary care under specialized metabolic centers has optimized outcomes
transforming Refsum disease from a uniformly fatal to now a manageable chronic disorder
for the majority. With ongoing research into pathogenesis, newer therapeutic targets like gene
therapy hold promise for a cure or disease modification in future.
Conclusion
In summary, Refsum disease is an extremely rare inherited disorder of peroxisomal phytanic
acid metabolism categorized under the group of peroxisomal biogenesis disorders. It
classically presents with a characteristic triad of progressive sensory motor neuropathy,
retinopathy and cardiomyopathy affecting multiple systems over the decades. Advancements
in our understanding of its genetic defects and pathophysiological mechanisms have greatly
facilitated early diagnosis through demonstration of elevated plasma and tissue phytanic acid
levels. An individually tailored multi-pronged management strategy focusing on phytanic
acid lowering through restricted diets, plasmapheresis and supportive care aims to stabilize
neurological, ocular and cardiac involvement thereby improving long term functional status
and survival. Earlier institution of specific therapies especially in less symptomatic phases
appears paramount for optimal outcomes thereby transforming previous dismal prognoses.
With continued research initiatives, more definitive and curative interventions for this
complex metabolic disorder may emerge in future.
